# Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

> **NCT05626400** · NA · RECRUITING · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** Senl-T7

## Key facts

- **NCT ID:** NCT05626400
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-29
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626400, "Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05626400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*